Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & EMBASE  
     Home | Subscribe | Feedback  

DRUG REVIEW
[View FULLTEXT] [Download PDF
 
Year : 2012  |  Volume : 58  |  Issue : 3  |  Page : 203-206  

Abiraterone acetate: A novel drug for castration-resistant prostate carcinoma

R Nandha 
 Department of Pharmacology, Dr. HSJIDS, Panjab University, Sector 25, Chandigarh, Punjab, India

Correspondence Address:
R Nandha
Department of Pharmacology, Dr. HSJIDS, Panjab University, Sector 25, Chandigarh, Punjab
India

Androgen-deprivation therapy is the mainstay of treatment for the management of advanced prostate carcinoma till transition to castration-resistant prostate carcinoma (CRPC). Recently, adrenal and intratumoral synthesis of androgens has been found to be the major cause for CRPC. Abiraterone acetate is an orally active, potent and selective inhibitor of 17 a hydroxylase and c 17, 20 lyase, which acts by decreasing the de novo production of androgens with no rise in steroids downstream. Multiple randomized trials have shown significant improvement of >50% decline in prostate-specific antigen (PSA) and time to PSA progression (TTPP) with abiraterone acetate 1000 mg per day in chemotherapy/ketoconazole treated and naive CRPC patients producing reversible and manageable adverse effects due to mineralocorticoid excess. This article reviews the available evidence on efficacy and safety of this drug in CRPC. Searches of Pubmed, Cochrane database, Medscape, Google and clinicaltrial.org were made for terms like CRPC and abiraterone.


How to cite this article:
Nandha R. Abiraterone acetate: A novel drug for castration-resistant prostate carcinoma.J Postgrad Med 2012;58:203-206


How to cite this URL:
Nandha R. Abiraterone acetate: A novel drug for castration-resistant prostate carcinoma. J Postgrad Med [serial online] 2012 [cited 2020 Nov 25 ];58:203-206
Available from: https://www.jpgmonline.com/article.asp?issn=0022-3859;year=2012;volume=58;issue=3;spage=203;epage=206;aulast=Nandha;type=0


 
Wednesday, November 25, 2020
 Site Map | Home | Contact Us | Feedback | Copyright  and disclaimer